Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00853762
Other study ID # 28851
Secondary ID
Status Terminated
Phase Phase 2
First received February 26, 2009
Last updated February 3, 2012
Start date February 2009
Est. completion date February 2011

Study information

Verified date February 2012
Source EMD Serono
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationBelgium: Federal Agency for Medicinal Products and Health Products
Study type Interventional

Clinical Trial Summary

This study, 28851, is a long-term follow-up study of subjects enrolled in ATAMS study 28063, the aim of which is to monitor the safety and tolerability of atacicept administered for up to 5 years to subjects with relapsing multiple sclerosis (RMS).

This extension study consists of two parts. Part A will be double blind and Part B will be open label. During Part A subjects initially randomized to atacicept will continue to receive the atacicept dose to which they have been randomized in study 28063 (ATAMS) once a week sub cutaneously (under the skin). Subjects randomized to placebo in ATAMS will receive atacicept at 150 mg once a week sub cutaneously during Part A. Once the results of ATAMS are available and the atacicept dose with the best benefit / risk ratio has been identified, all subjects will be switched to this dose and will continue the extension study open-label (Part B). Throughout the study, subjects and investigators will remain blinded with respect to intial and part A treatment allocation/dose.


Recruitment information / eligibility

Status Terminated
Enrollment 68
Est. completion date February 2011
Est. primary completion date September 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Participation in study 28063.

- Completion of Week 36 visit of the core study 28063.

- Willingness and ability to comply with study procedures for the duration of the study.

- Voluntary provision of written informed consent (including, for the USA, subject authorization under the Health Insurance Portability and Accountability Act (HIPAA)), given before any study-related procedure that is not part of normal medical care and with the understanding that the subject may withdraw consent at any time without prejudice to his or her future medical care.

Exclusion Criteria:

- Premature discontinuation of core study 28063.

- Subjects who meet criteria listed below will receive IMP in study 28851.

- Subjects who are eligible for participation in extension study 28851 but do not meet these criteria will not be treated with IMP but will undergo scheduled visits, irrespective of their treatment.

- All subjects must satisfy the following criteria before Extension Study Day 1 (D1-EXT; defined as the first day of dosing in the extension study) to be eligible for treatment with IMP:

- Eligibility for participation in extension study 28851.

- For women of childbearing potential, a negative urine pregnancy test at eligibility assessment.

- Female subjects of childbearing potential must be willing to avoid pregnancy by using an adequate method of contraception for four (4) weeks before the first dose administered within the extension study, during the study and for twelve (12) weeks after the last dose of trial medication. Adequate contraception is defined as two barrier methods, or one barrier method with spermicide, or an intrauterine device, or use of a combined oral female hormonal contraceptive (or the definitions requested by health authorities and locally amended in the core study 28063). For the purposes of this trial, women of childbearing potential are defined as: "All female subjects after puberty unless they are post-menopausal for at least two years or are surgically sterile" (For Germany Only: Female subjects of childbearing potential must be willing to avoid pregnancy by using highly effective methods of contraception for approximately four (4) weeks prior to D1-EXT, during and for twelve (12) weeks after the last dose of trial medication. This requirement does not apply to surgically sterile subjects or to subjects who are postmenopausal for at least 2 years. Highly effective contraception is defined as any method or combination of methods which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, sexual abstinence, vasectomized partner, two barrier methods, or one barrier method with spermicide)

- Willingness and ability to comply with study procedures for the duration of the study.

- To be eligible for treatment with IMP in study 28851, the subjects must not meet any of the following criteria:

- Non-eligibility for participation in extension study 28851 (premature discontinuation of core study 28063).

- Major protocol violation or non-compliance in the core study.

- Use of prohibited immunomodulatory / immunosuppressive therapies

- Serum IgG level <3 g/L if the subject received atacicept in the core study, or serum IgG level <6 g/L if the subject received placebo in the core study (to protect the blinding of the core study, the IgG level will be communicated to the treating physician only if it is too low for extension study participation and only after all Week 36 assessments performed within the core study have been completed).

- Any condition, including laboratory findings that, in the opinion of the Investigator, constitutes a risk or a contraindication for participation in the extension study, or that could interfere with the study objectives, conduct or evaluation.

- Known active clinically significant acute or chronic infection, or any major episode of infection requiring hospitalization or treatment with parenteral anti-infectives.

- Investigator judgment that treatment of the subject with atacicept in the extension study is not appropriate.

- Aspartate aminotransferase (AST), or alanine aminotransferase (ALT), or alkaline phosphatase (AP) level >2.5 x upper limit of normal (ULN), or total bilirubin >1.5 x ULN at eligibility assessment.

- Clinically significant abnormality in any hematological test (e.g. hemoglobin <100 g/L (6.21 mmol/L), white blood cells <3 x 109/L, platelets <100 x 109/L) at eligibility assessment.

- Clinically significant abnormality on ECG performed at eligibility assessment.

- Presence of uncontrolled or New York Health Association (NYHA) class 3 or 4 congestive heart failure at Week 36 of the core study.

- Moderate to severe renal impairment (creatinine clearance <50 mL/min according to Cockcroft-Gault equation).

- Allergy or hypersensitivity to gadolinium (Gd).

- Allergy or hypersensitivity to atacicept or to any of the components of the formulated atacicept.

- Diagnosis or family history of Creutzfeldt-Jakob disease (CJD).

Study Design

Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Intervention

Drug:
Atacicept
During Part A subjects will continue to receive the atacicept dose to which they have been randomized in study 28063 (ATAMS) i.e. 25mg once a week (QW) subcutaneously (SC), 75mg QW SC or 150mg QW SC. Subjects randomized to placebo in ATAMS will receive atacicept 150mg QW SC without loading dose. Once the results of ATAMS are available and the atacicept dose with the best benefit/risk ratio has been identified, all subjects will be switched to this dose and will continue the extension study open-label (Part B). The study treatment period will be up to five years starting from first administration of the first dose of atacicept from the core study (28063 - ATAMS).
Atacicept
Best benefit / risk ratio treatment of Atacicept dose that has been identified

Locations

Country Name City State
Australia Research Site Box Hill VIC
Australia Research Site Fitzroy
Australia Research Site New Lambton
Australia Research Site Woodville
Belgium Research Site Diepenbeek
Belgium Research Site Sijsele
Canada Research Site Calgary Alberta
Canada Research Site Ottawa Ontario
Czech Republic Research Site Brno
Czech Republic Research Site Hradec Králové
France Research Site Caen
France Research Site Saint-Herblain
Germany Research Site Bochum
Germany Research Site Düsseldorf
Lebanon Research Site Beyrouth
Lithuania Research Site Kaunas
Netherlands Research Site Breda
Netherlands Research Site Nieuwegein
Netherlands Research Site Rotterdam
New Caledonia Research Site Winston Salem
Russian Federation Research Site Ekaterinburg
Russian Federation Research Site Moscow
Russian Federation Research Site Novosibirsk
Russian Federation Research Site Saint Petersburg
Russian Federation Research Site Samara
Russian Federation Research Site Vladimir
Russian Federation Research Site Yaroslavl
Spain Research Site Barcelona
Spain Research Site Madrid
Spain Research Site Malaga
Sweden Research Site Stockholm
Switzerland Research Site Basel
Switzerland Research Site Innsbruck
Switzerland Research Site Zürich
Ukraine Research Site Kharkiv
Ukraine Research Site Kyiv
Ukraine Research Site Odessa
Ukraine Research Site Uzhgorod
United Kingdom Research Site London
United Kingdom Research Site Sheffield
United Kingdom Research Site Stoke on Trent
United States Research Site Cleveland Ohio
United States Research Site Cleveland, Ohio
United States Research Site East Lansing Michigan
United States Research Site Nashville Tennessee
United States Research Site Northbrook Illinois
United States Research Site Philadelphia Pennsylvania
United States Research Stie Phoenix Arizona

Sponsors (1)

Lead Sponsor Collaborator
EMD Serono

Countries where clinical trial is conducted

United States,  Australia,  Belgium,  Canada,  Czech Republic,  France,  Germany,  Lebanon,  Lithuania,  Netherlands,  New Caledonia,  Russian Federation,  Spain,  Sweden,  Switzerland,  Ukraine,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Nature and severity of AEs and SAEs (i.e. infections, injection site reactions and malignancies) at each visit At each visit No
Primary Hematology, and blood chemistry laboratory parameters and vital signs at each visit At each visit No
Primary ECGs At SD 1, W12, W36, once per year starting at W60, and at long term follow up, early study termination and early treatment termination visits No
Primary IgG levels (i.e. IgG level <3 g/L) Will be monitored for the duration of the study No
Primary Immunogenicity: development of NAb to atacicept, persistence of NAb in subjects who become NAb-positive either in the core study or in the extension study will be assessed at each study visit at each study visit At each study visit No
Secondary Number of clinical attacks/relapses for duration of study Duration of study No
Secondary EDSS and KFS scores At W12, W36, 1x per year starting at W60, Early Study Termination (EST) and Early Treatment Termination (ETT) visits No
Secondary MSFC score At W12, W36, once per year starting at W60, EST and ETT visits No
Secondary MRI parameters At W12, once per year starting at W60, W228 and possibly at EST and ETT visits No
Secondary PK measures At W12, W36, W60, W216, W228 and at EST or ETT visit No
Secondary PD measures At each visit No
Secondary Pharmacogentics/pharmacogenomics analysis in a subgroup of patients At W12 and 1x per year from W60 No
See also
  Status Clinical Trial Phase
Recruiting NCT04121065 - Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS)
Active, not recruiting NCT03996291 - Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis Phase 2
Recruiting NCT04510220 - 9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis Phase 3
Terminated NCT02241785 - Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis (MS) After Failure on Other Therapies Phase 4
Completed NCT02792218 - Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis Phase 3
Completed NCT01412333 - A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis Phase 3
Completed NCT03257358 - A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod Phase 4
Completed NCT01628393 - Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients Phase 2/Phase 3
Completed NCT04626921 - A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis Phase 2/Phase 3
Withdrawn NCT02234869 - Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy Phase 4
Withdrawn NCT05077956 - Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis
Active, not recruiting NCT04486716 - A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis Phase 3
Recruiting NCT04121403 - Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS) Phase 3
Recruiting NCT05809986 - Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study
Terminated NCT00988052 - A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course Phase 3
Active, not recruiting NCT05232825 - A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis Phase 3
Terminated NCT01047319 - A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis Phase 3
Completed NCT04847596 - A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
Completed NCT01127750 - Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients Phase 3
Completed NCT01006941 - Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study Phase 2